EWTX Edgewise Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why EWTX matters now
Edgewise Therapeutics, Inc. (EWTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $45.41 with -6.08% on the session and $4.89B in market capitalization; recent performance reads 1-month +17.12% and YTD +48.31%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-49.0M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.00; recent insider activity includes Morris Arlene filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.99
P/S
0.00
EV/EBITDA
-22.34
DCF Value
$0.50
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-33.9%
ROIC
-40.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-49.0M | $-0.46 |
| Q4 2025 | $0.00 | $-50.2M | $-0.47 |
| FY 2025 | $0.00 | $-167.8M | $-1.63 |
| Q3 2025 | $0.00 | $-40.7M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$47.56
Target (Median)
$52.00
Target Range
$25.00 - $66.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.30
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.